Topic
weight-loss
Business Weight-loss jabs reshape UK shopping habits, cutting grocery spending by £780m
New research reveals that more than two million UK users of weight-loss drugs like Wegovy and Mounjaro are significantly altering their spending patterns. Households with GLP-1 users spend an average of £418 less on groceries annually, contributing to a £780m national decline. The shift extends to product choices, with reduced purchases of chocolate, pastries and alcohol, and increased spending on protein-rich foods, mouthwash and hair dyes – the latter to counter common side effects. Retailers and food manufacturers are adapting product sizes and marketing strategies.
Manufacturing Wegovy Weight Loss Pill Now Available Privately in UK Pharmacies, Offers Needle-Free Alternative
The once-a-day Wegovy weight loss pill, containing semaglutide, is now available to buy privately from High Street and online pharmacies in the UK. It offers an alternative to the injection, with similar effectiveness, but requires strict dosing guidelines including fasting before each dose. Key differences and eligibility criteria are outlined.
Manufacturing Just About Anyone Can Sell GLP-1s Online Now: Turnkey Telehealth Sparks Market Flood
The rise of turnkey telehealth services is enabling companies with no medical background—from search platforms like JustAnswer to dating apps like Grindr—to sell GLP-1 drugs online. Infrastructure firms handle software, clinician networks, and compliance, allowing new entrants to launch in as little as three hours. The trend is accelerating rapidly, with one provider reporting a minimum of one new brand launch per day.
Semaglutide therapy market faces Rs 100 crore excess stock after initial rush
The Indian semaglutide therapy market is facing an excess stock of approximately Rs 100 crore, with stockists holding 50-60 days of inventory after a sharp slowdown in May sales. The market had surged following patent expiry in March but growth slowed drastically, leading to a halt in fresh procurement from pharmaceutical companies.